Posted on Mar 8th 2019
Researchers have discovered that inhibition of RIP1 kinase blocks the progression of multiple sclerosis in an immune-induced demyelination mouse model (EAE) but not a chemically-induced one (CPZ). RIPA-56 (Focus Biomolecules Cat# 10-4611) blocked disease progression at a step of monocyte elevation downstream of T-cell activation and myelin-specific antibody generation but upstream of blood-brain barrier breakdown. This represents a previously unknown function of RIP1 kinase and offers a potential new therapeutic opportunity for treatment of immune system mediated demyelinating diseases such as multiple sclerosis.
Multiple cellular pathways can lead to acquired resistance to ALK inhibitors. A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R to maintain activation of downstream ERK and/or PI3K-AKT signaling. Addition of inhibitors to these pathways is a viable response, but not optimal due to the presence of multiple alternatives. Dardaei [...]
Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone receptors that are critical components of the circadian clock, the body's mechanism for establishing daily rhythms in cellular proliferation, metabolism, and other essential processes. Dysregulation of this system is [...]